A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma Investigator Kethandapatti Balaji Ages 18 Years - 100 Years Sexes All